Edition:
United Kingdom

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

57.40USD
15 Dec 2017
Change (% chg)

$1.72 (+3.09%)
Prev Close
$55.68
Open
$55.78
Day's High
$57.87
Day's Low
$55.78
Volume
568,366
Avg. Vol
128,575
52-wk High
$97.14
52-wk Low
$45.05

Summary

Name Age Since Current Position

Michael Graves

54 2016 Independent Chairman of the Board

Scott Tarriff

57 2017 Chief Executive Officer, Independent Director

Pete Meyers

47 2017 Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer

David Riggs

65 2013 Chief Financial Officer

Steven Krill

57 2015 Executive Vice President, Chief Scientific Officer

Adrian Hepner

55 2016 Executive Vice President, Chief Medical Officer

Douglas Braunstein

56 2016 Independent Director

Richard Edlin

56 2017 Independent Director

Sander Flaum

80 2007 Independent Director

Robert Glenning

56 2016 Independent Director

Steven Ratoff

74 2007 Independent Director

Lisa Wilson

2017 IR Contact Officer

Biographies

Name Description

Michael Graves

Mr. Michael Graves is Independent Chairman of the Board of Eagle Pharmaceuticals, Inc. Mr. Graves has served as a member of Board since November 2013. In January 2012 Mr. Graves joined the Board of Directors of RiboCor, Inc. and in December 2013, Mr. Graves was appointed chairman of the Board of Directors of Nanocopoeia, Inc., both private pharmaceutical companies. From May 2007 to July 2011, Mr. Graves served as the chief executive officer and president of Paddock Laboratories, Inc., a pharmaceutical company engaged in the manufacture, distribution and marketing of bioequivalent generic pharmaceuticals. From September 2005 to November 2006, Mr. Graves served as president of the generic products division at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals. While at Par, Mr. Graves oversaw the strategy development of Par's generic pharmaceutical business. Beginning in 1998, Mr. Graves served as director of marketing and sales operations of Par, and in 2004, Mr. Graves was promoted to senior vice president of corporate development and strategic planning. Mr. Graves served in this position until his promotion to president of the generic products division in September 2005. Mr. Graves holds a B.S. from State University College of New York at Buffalo. Mr. Graves has extensive experience in marketing, sales, business development and operations.

Scott Tarriff

Mr. Scott L. Tarriff is Chief Executive Officer, Independent Director of Eagle Pharmaceuticals, Inc. Mr. Tarriff is founder and has served as our President and Chief Executive Officer and as a member of Board since inception in January 2007. Prior to joining Eagle, Mr. Tariff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par's Board of Directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and previously served on the Board of Directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College. The Board believes that Mr. Tarriff's extensive knowledge of our business, his management experience in the pharmaceutical industry, as well as his operational , expertise.

Pete Meyers

Mr. Pete A. Meyers has been appointed as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer of the Company. He most recently served as the Chief Financial Officer of Motif BioSciences Inc. (NASDAQ: MTFB; AIM: MTFB) from April 2016 to January 2017, where he led the execution of the company’s November 2016 U.S. IPO. From August 2013 to March 2016, Mr. Meyers served as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG), where he led the execution of the company’s December 2013 IPO and subsequent acquisition of Shape Pharmaceuticals, Inc. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr. Meyers currently serves on the Board of Directors of Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR), where he chairs the audit committee. Mr. Meyers is also the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc. He earned a Bachelor of Science degree in Finance from Boston College and a Master of Business Administration degree from Columbia Business School.

David Riggs

Mr. David E. Riggs is Chief Financial Officer of Eagle Pharmaceuticals, Inc. From May 2010 to October 2013, Mr. Riggs served as a healthcare consultant at various biotechnology and pharmaceutical companies. From March 2006 to May 2010, Mr. Riggs served as chief financial officer of Ferring Pharmaceuticals Inc., a private biopharmaceutical company devoted to isolating, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis. From January 2003 to September 2005, Mr. Riggs held various positions at eXegenics Inc., a publicly-traded pharmaceutical company that is now OPKO Health, Inc., including most recently as its chief executive officer. Mr. Riggs served as senior vice president and chief financial officer of Axys Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, from March 2000 until it was acquired by Applera Corporation in November 2001. From February 1992 to February 2000, Mr. Riggs held various positions at Unimed Pharmaceuticals, Inc., a private company focused on developing and commercializing products in human immunodeficiency virus, oncology and urology specialty markets. Previously, Mr. Riggs held various positions at Fujisawa Pharmaceuticals, Inc., a private pharmaceutical company that was acquired by Astellas Pharma Inc., including treasurer and director of financial planning and analysis. Mr. Riggs holds a B.S. in accounting from the University of Illinois and an M.B.A. from DePaul University.

Steven Krill

Mr. Steven L. Krill, Ph.D., is Executive Vice President, Chief Scientific Officer of Eagle Pharmaceuticals, Inc. Dr. Krill He has held the position of Chief Scientific Officer since February 2013. He held the position of Vice President of Pharmaceutical Development from October 2011 to February 2013. Dr. Krill served as the vice president of Scientific Affairs at Teva Parenteral Medicines from March 2009 to August 2011. Dr. Krill held the positions of Vice President Pharmaceutical Research and Development (December 2005 until March 2009) and Director of Pharmaceutics and Investigational Supplies (from May 2002 to December 2005) at Boehringer Ingelheim. Prior to that, Dr. Krill held various management positions at Lipocine Inc., Novartis Pharmaceuticals and Abbott Laboratories Dr. Krill is an author of over 30 publications and inventor of multiple patents in the area of drug delivery. Dr. Krill holds a B.S. in pharmacy and an M.S. in pharmaceutical sciences from the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah.

Adrian Hepner

Dr. Adrian J. Hepner, M.D. Ph.D, is Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc. Previously served as Executive Vice President, Clinical Research, Medical & Regulatory Affairs of the company, From January 2015 to January 2016. Dr. Hepner has over 25 years of U.S. and international experience in clinical studies and has been involved in filing of multiple INDs and NDAs. Dr. Hepner trained first as a physician and later as a neuropsychiatrist at the University of Buenos Aires School of Medicine. He also spent a number of years as a post-doctoral fellow in neuropsychopharmacology at the University of Ottawa. Following his post-doctoral fellowship Dr. Hepner was a clinical consultant to a number of pharmaceutical companies and a leading clinical investigator in Latin America. In 2001, he joined IVAX Corporation where he was director of new drug development. Prior to joining Eagle he was Vice President of Clinical Research and Medical Affairs at Biodelivery Sciences International, Vice President of Clinical Research and Medical Affairs at Avanir Pharmaceuticals and director of innovative R&D at TEVA Pharmaceuticals. Dr. Hepner has over 30 publications and has also received an award from the National Academy of Medicine in Argentina for his research work in dementias.

Douglas Braunstein

Mr. Douglas L. Braunstein is Independent Director of Eagle Pharmaceuticals, Inc.. Mr. Braunstein has 30 years of industry experience, currently serving as a managing partner and co-founder of Hudson Executive Capital LP. Previously, Mr. Braunstein served in various roles at JPMorgan Chase & Co., including as vice chairman from 2013 to 2014, chief financial officer from 2010 to 2012, and also serving as a member of the company's operating committee from 2010 to 2012, head of Americas investment banking and global M&A from 2008 to 2010, and global head of industry coverage from 2002 to 2007 and M&A from 1997 to 2007. Mr. Braunstein graduated from Harvard Law School with a J.D. and from Cornell University with a B.S. in industrial and labor relations. Our board of directors believes that Mr. Braunstein's extensive executive experience and background in investment strategy and banking as well as his strong financial background qualifies him to serve on our board of directors.

Richard Edlin

Mr. Richard A. Edlin is Independent Director of the company. Mr. Edlin is a seasoned litigator with broad experience in both trial and appellate courts including the U.S. Supreme Court and the Delaware Supreme Court. He has tried cases in federal and state courts all over the country and has handled domestic and international arbitrations. At Greenberg Traurig, Mr. Edlin handles a wide variety of litigation and routinely acts for companies and their management in areas such as securities, general commercial and contractual disputes, antitrust and intellectual property. Mr. Edlin is a member of the Board of Trustees of the Urban Justice Center; a member of the Board of Directors for Judges and Lawyers Breast Cancer Alert (JALBCA); a member of the Board of Governors of Hackensack University Medical Center, where he serves on the finance committee; a trustee of The Carnegie Council for Ethics in International Affairs, where he serves as Treasurer and chairs the development and finance committees; a member of the Board of Governors, American Friends of Tel Aviv University; a member of the Economic Club of New York; a fellow of the Litigation Council of America; and a trustee of New Jersey SEEDS, among other professional and community activities.Mr. Edlin received his B.A. degree from Tufts University, magna cum laude in history and received his law degree from Columbia University School of Law, where he was a Harlan Fiske Stone Scholar and Notes editor of the Columbia Journal of Environmental Law. Following his graduation, Mr. Edlin served as law clerk to Hon. Lee P. Gagliardi of the United States District Court for the Southern District of New York.

Sander Flaum

Mr. Sander A. Flaum is Independent Director of Eagle Pharmaceuticals, Inc. Mr. Flaum has served as a principal of Flaum Navigators, a healthcare strategic and marketing insights firm that he founded. From 1988 to 2003, Mr. Flaum served as chief executive officer of Robert A. Becker, Euro RSCG, a global communications company and a predecessor to Havas Life. Prior to that, Mr. Flaum held various positions during an 18-year career at Lederle Laboratories, a top-ranked pharma company that is now Pfizer. At Lederle, he served as marketing director of prescription products, vaccines and generics. Mr. Flaum now serves on the Board of Directors of the Fisher College of Business at The Ohio State University, The James Cancer Center at the OSU Medical Center, the Fordham University Gabelli Graduate School of Business, the American Institute for Stuttering and Lime Connect. Mr. Flaum is an Adjunct Professor of Leadership at the Fordham University Gabelli Graduate School of Business, where he also chairs the Fordham Leadership Forum and serves as Executive-In-Residence. Mr. Flaum holds a B.A. from The Ohio State University and an M.B.A. from Fairleigh Dickinson University. Mr. Flaum's has extensive experience in the pharmaceutical and biotech industries.

Robert Glenning

Mr. Robert L. Glenning is Independent Director of Eagle Pharmaceuticals, Inc. Mr. Glenning has over 30 years of experience in the healthcare industry and since July 2016 has served as the president of the financial services division and chief financial officer at Hackensack Meridian Health, the most comprehensive health delivery network in the state of New Jersey. From 2007 to June 2016, he served as executive vice president and chief financial officer of Hackensack University Health Network. From 2002 - 2007, Robert served as an executive vice president and chief financial officer of Kaleida Health Inc., the largest healthcare system in western NY. Prior to Kaleida Health, he served as vice president and chief financial officer of acute care at Northeast Health and Albany Memorial Hospital. Robert began his career at PricewaterhouseCoopers. He earned his BBA from Siena College and his MBA from Clarkson University. He is a Certified Public Accountant (license currently inactive). Our board of directors believes that Mr. Glenning's has executive experience and background in the healthcare industry.

Steven Ratoff

Mr. Steven B. Ratoff is Independent Director of Eagle Pharmaceuticals, Inc., Mr. Ratoff is founder and has served as President and Chief Executive Officer and as a member of Board since inception in January 2007. Prior to joining Eagle, Mr. Tariff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par's Board of Directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and previously served on the Board of Directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College. Mr. Ratoff's has extensive executive experience and background in the global pharmaceutical and consumer products industries .

Lisa Wilson

Basic Compensation

Name Fiscal Year Total

Michael Graves

743,316

Scott Tarriff

7,152,150

Pete Meyers

--

David Riggs

2,550,340

Steven Krill

2,473,820

Adrian Hepner

3,095,660

Douglas Braunstein

155,475

Richard Edlin

--

Sander Flaum

502,619

Robert Glenning

159,225

Steven Ratoff

503,869

Lisa Wilson

--
As Of  31 Dec 2016